Christian Valencia Pineda, Vice President and World Wide Disease Area Head, Solid Tumors at Bristol Myers Squibb shared a post on LinkedIn:
“Gastrointestinal (GI) cancers remain one of the greatest areas of unmet need in oncology. It is encouraging to see this field evolving into a multi-asset, multi-mechanism therapeutic landscape, creating new opportunities for patients across a broad range of gastrointestinal malignancies.
I am proud of our team for continuing to advance innovative science and working every day to expand treatment options for patients.
ESMO GI 2026 was a meaningful opportunity to share progress, collaborate with colleagues, and discuss the future of gastrointestinal cancer research and treatment.
Looking ahead, there is continued momentum toward improving outcomes for patients with GI cancers.”
Other articles about ESMO on OncoDaily.
